MedWatch

Covid-19 created many attractive opportunities for Novo Holdings in 2020

Even though Covid-19 caused a volatile market situation in 2020, the overall tailwind for the life science sector has also boosted Novo Holdings' life science investment portfolio, states CEO Kasim Kutay.

Novo Holdings Kasim Kutay CEO | Photo: Novo Holdings / PR

The markets were in the middle of a heavy dive last year in March, when Novo Holdings presented its annual report. However, the holding and investment company saw major potential in this dive, and far along the way, the potential has been realized, Novo Holdings CEO tells Kasim Kutay.

"Looking at the overall performance of 2020, you have to conclude that we did very well, life science has had a very good year," he says, referring to the fact that Novo Holdings has earned the record sum of DKK 29bn (USD 4.6bn) in 2020.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs